Adverse events, treatment discontinuations, and deaths in the safety population
| . | High risk . | Standard risk . | Unknown . | |||
|---|---|---|---|---|---|---|
| KRd (n = 46) . | Rd (n = 51) . | KRd (n = 146) . | Rd (n = 168) . | KRd (n = 200) . | Rd (n = 170) . | |
| Any grade ≥3 TEAE, n (%) | 41 (89.1) | 40 (78.4) | 125 (85.6) | 142 (84.5) | 162 (81.0) | 132 (77.6) |
| Treatment discontinuations of any study drug attributable to adverse events, n (%) | 12 (26.1) | 12 (23.5) | 33 (22.6) | 45 (26.8) | 57 (28.5) | 40 (23.5) |
| Deaths within 30 d of last dose, n (%) | 4 (8.7) | 2 (3.9) | 9 (6.2) | 12 (7.1) | 17 (8.5) | 19 (11.2) |
| . | High risk . | Standard risk . | Unknown . | |||
|---|---|---|---|---|---|---|
| KRd (n = 46) . | Rd (n = 51) . | KRd (n = 146) . | Rd (n = 168) . | KRd (n = 200) . | Rd (n = 170) . | |
| Any grade ≥3 TEAE, n (%) | 41 (89.1) | 40 (78.4) | 125 (85.6) | 142 (84.5) | 162 (81.0) | 132 (77.6) |
| Treatment discontinuations of any study drug attributable to adverse events, n (%) | 12 (26.1) | 12 (23.5) | 33 (22.6) | 45 (26.8) | 57 (28.5) | 40 (23.5) |
| Deaths within 30 d of last dose, n (%) | 4 (8.7) | 2 (3.9) | 9 (6.2) | 12 (7.1) | 17 (8.5) | 19 (11.2) |
TEAE, treatment-emergent adverse event.